• Skip to content

Biotech Animated

Biotech Animated | Biotechnology & Life-Science Animation | Beautifully Deliver Your Life-science Company’s Message to a Greater Audience | Biotech Animated is a Life-Science Animation, Advertising Strategy and Business Development Firm

Main navigation

  • Projects
  • About
  • What We Do
  • Our Story
  • Team
  • Join Us
  • Contact Us

DMX-200 – A Novel Approach to Chronic Kidney Disease

*Please scroll down to the bottom of the page for the final deliverable.

Project Overview

Dimerix is a clinical stage biotechnology company focused on developing new therapeutics discovered using their proprietary drug development Receptor-Heteromer Investigation Technology platform. Dimerix’s lead therapy DMX-200 is currently in Phase II clinical trials for chronic kidney disease and has received US Orphan Drug Designation for Focal Segmental Glomerulosclerosis.

The primary objective of this project is to attract the interest of investors. The secondary objective is to create new business partnerships. This is done through a primary video (video 1) which explains the mechanism of action of Dimerix’s lead therapy.

The target audience for video 1 is non-scientific lay persons. They may have a general understanding of some of the scientific concepts surrounding kidney disease and are likely to be quite an intelligent audience. Nonetheless the video needs to be pitched at non-scientists.

Storyboard

dimerix-1-mp4_000008224

Affecting over ten percent of the population, chronic kidney disease, or CKD, is a major global health problem.

dimerix-1-mp4_000013245

Sufferers experience reduced quality of life and a shortened life expectancy, and many ultimately require dialysis.

dimerix-1-mp4_000021524

Current therapeutic approaches only slow disease progression towards kidney failure and new approaches are needed,

dimerix-1-mp4_000026854

which is why Dimerix is developing DMX-200, an innovative new therapy in clinical trials.

dimerix-1-mp4_000031514

What is CKD?

dimerix-1-mp4_000034166

CKD includes a number of different conditions where the kidneys are damaged

dimerix-1-mp4_000039442

and no longer able to efficiently filter waste out of the blood.

dimerix-1-mp4_000045149

For many CKD patients, damage stems from an abnormal inflammation response where the immune system inappropriately attacks kidney cells.

dimerix-1-mp4_000057160

This attack compromises the kidney’s ability to filter the blood, permitting leakage of abnormally high levels of protein from the blood into the urine,

dimerix-1-mp4_000060775

a condition called proteinuria.

dimerix-1-mp4_000065795

Unfortunately, proteinuria itself is also believed to cause kidney damage,

dimerix-1-mp4_000068752

compounding cellular injury and disease progression.

dimerix-1-mp4_000077972

The current standard of care for patients with CKD includes blood pressure-lowering treatments such as irbesartan, a drug that reduces the rate of protein leakage into the urine.

dimerix-1-mp4_000086624

However, the loss of kidney function continues unless the damage caused by inflammation is controlled, leaving many treatment options ineffective.

dimerix-1-mp4_000092334

Why DMX-200?

dimerix-1-mp4_000095245

DMX-200 attacks CKD in a groundbreaking way by adding a registered anti-inflammatory drug

dimerix-1-mp4_000100537

to the blood pressure lowering drug irbesartan.

dimerix-1-mp4_000110087

Unlike other treatments, these molecules work synergistically to block signals that attract the inflammation-causing immune cells to the kidney, limiting further damage.

dimerix-1-mp4_000120161

Preclinical studies have shown that together these drugs are more protective than either therapy alone, and clinical trials are already underway.

dimerix-1-mp4_000130962

Help bring this exciting new therapeutic approach to patients with CKD —learn more about investing by emailing info@dimerix.com.

Final Video Deliverable

 

This video is currently live here

  • Join Us
  • Contact Us

COPYRIGHT © 2023 BIOTECH ANIMATED